![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
ProShares Ultra Materials
UYM
SPDR S&P Metals & Mining ETF
XME
Ishares Trust U.S. Aerospace & Defense Etf
ITA
4
Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
5
iShares US Basic Materials ETF
IYM
US Stock MarketDetailed Quotes
MAIA Biotechnology (MAIA)
- 1.570
- -0.060-3.68%
Close Jan 12 15:59 ET
- 1.630
- +0.060+3.82%
Post 20:01 ET
58.14MMarket Cap-2.12P/E (TTM)
1.640High1.560Low323.56KVolume1.590Open1.630Prev Close515.86KTurnover1.01%Turnover RatioLossP/E (Static)37.03MShares2.74052wk High1570.00P/B50.21MFloat Cap0.87052wk Low--Dividend TTM31.98MShs Float9.640Historical High--Div Yield TTM4.91%Range %0.820Historical Low1.594Avg Price1Lot Size
MAIA Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
MAIA Orderflow
Unit: --
MAIA Orderflow Trend
IntradayDayWeekMonth
No Data
MAIA Biotechnology (MAIA) News
$MAIA Stock Is up 13% Today. Here's What We See in Our Data.
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
Insider Purchase: Director at $MAIA Buys 81,699 Shares
MAIA Biotechnology, Inc. (MAIA) Gets a Buy From Noble Financial
MAIA Biotechnology Announces $1.51M Private Placement Of 1.23M At A Price Of $1.224/Share With Warrants Exercisable At A Price Of $1.36/Share
Express News | Maia Biotechnology Announces $1.51 Million Private Placement
MAIA Biotechnology (MAIA) Stock Forum
$MAIA Biotechnology (MAIA.US)$ clown, they have insufficient funds to run full phase 3 trial. Unless they manage to secure non dilutive funds.
1
$MAIA Biotechnology (MAIA.US)$ MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
GlobeNewswire
Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine
CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immun...
GlobeNewswire
Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine
CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immun...
1
$MAIA Biotechnology (MAIA.US)$
MAIA Biotechnology Announces $1.51 Million Private Placement
Tuesday, 16th December at 4:15 pm
CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,233,488 shares of common stock at a purchase price of $1.2...
MAIA Biotechnology Announces $1.51 Million Private Placement
Tuesday, 16th December at 4:15 pm
CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,233,488 shares of common stock at a purchase price of $1.2...
1
$MAIA Biotechnology (MAIA.US)$ Reuters
just
Maia Biotechnology Announces $1.51 Million Private Placement
just
Maia Biotechnology Announces $1.51 Million Private Placement
1
13
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)